1051 related articles for article (PubMed ID: 27220757)
41. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
[No Abstract] [Full Text] [Related]
42. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
[TBL] [Abstract][Full Text] [Related]
43. Systematic Screening Using Luminex for De Novo C3d Fixing of Class II Donor-Specific Antibodies Is Correlated With Luminex Mean Fluorescence Intensity in Renal Transplant Patients.
Villemaire M; Jouve T; Bourdin A; Janbon B; Pinel N; Tetaz R; Terrier N; Rostaing L; Masson D; Malvezzi P
Exp Clin Transplant; 2019 Aug; 17(4):483-489. PubMed ID: 30346267
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients.
Yamada C; Huang Y; Norman S; Naik A; Moussa O; Samaniego M; Cooling L
J Clin Apher; 2018 Dec; 33(6):673-677. PubMed ID: 30321467
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity of Class I HLA but not preformed low MFI donor specific antibodies correlates with outcomes after first renal transplantation.
Lobashevsky A; Goggins W; Rosner K; Taber T
Transpl Immunol; 2017 Aug; 43-44():42-48. PubMed ID: 28629951
[TBL] [Abstract][Full Text] [Related]
46. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
47. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS
Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925
[TBL] [Abstract][Full Text] [Related]
48. De novo donor-specific HLA antibodies: biomarkers of pancreas transplant failure.
Mittal S; Page SL; Friend PJ; Sharples EJ; Fuggle SV
Am J Transplant; 2014 Jul; 14(7):1664-71. PubMed ID: 24866735
[TBL] [Abstract][Full Text] [Related]
49. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
[TBL] [Abstract][Full Text] [Related]
50. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
51. The results of HLA-incompatible kidney transplantation according to pre-transplant crossmatch tests: Donor-specific antibody as a prominent predictor of acute rejection.
Kwon H; Kim YH; Kim JY; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2019 May; 33(5):e13533. PubMed ID: 30864255
[TBL] [Abstract][Full Text] [Related]
52. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
53. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
54. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
Wozniak LJ; Hickey MJ; Venick RS; Vargas JH; Farmer DG; Busuttil RW; McDiarmid SV; Reed EF
Transplantation; 2015 Jul; 99(7):1416-22. PubMed ID: 26038872
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
56. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
[TBL] [Abstract][Full Text] [Related]
57. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
58. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
[TBL] [Abstract][Full Text] [Related]
59. Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years.
Aziz F; Jung-Hynes B; Parajuli S; Redfield RR; Astor BC; Mandelbrot D; Hidalgo L; Djamali A
Clin Nephrol; 2020 Nov; 94(5):245-251. PubMed ID: 32870149
[TBL] [Abstract][Full Text] [Related]
60. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
Cheng EY; Kaneku H; Farmer DG
Clin Transpl; 2014; ():153-9. PubMed ID: 26281140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
